In this study, we illustrate that a novel NQO1 bioactivatable drug, IP-DNQ, effectively eradicates NQO1-positive cancer cells by inducing both apoptosis and programmed necrosis, displaying remarkable antitumor potential compared with previously tested NQO1 bioactivatable drugs. Here, NQO1 is linked to cancer.